Background. Anti-CD154 monotherapy is associated with antidonor allo-antibody (Ab) elaboration, cardiac allograft vasculopathy (CAV), and allograft failure in preclinical primate cell and organ transplant models. In the context of calcineurin inhibitors (CNI), these pathogenic phenomena are delayed by preemptive "induction" B cell depletion. Methods. αCD154 (IDEC-131)-treated cynomolgus monkey heart allograft recipients were given peritransplant rituximab (αCD20) alone or with rabbit antihuman thymocyte globulin. Results. Relative to previously reported reference groups, αCD20 significantly prolonged survival, delayed Ab detection, and attenuated CAV within 3 months in αCD154-treated recipients (αCD154 + αCD20 graft median survival time > 90 days, n = 7, vs 28 days for αCD154 alone (IDEC-131), n = 21; P = 0.05). Addition of rabbit antihuman thymocyte globulin to αCD154 (n = 6) or αCD154 + αCD20 (n = 10) improved graft protection from graft rejection and failure during treatment but was associated with significant morbidity in 8 of 16 recipients (6 infections, 2 drug-related complications). In αCD20-treated animals, detection of antidonor Ab and relatively severe CAV were anticipated by appearance of CD20 + cells (>1% of lymphocytes) in peripheral blood and were associated with low αCD154 trough levels (below 100 μg/mL). Conclusions. These observations support the hypothesis that efficient preemptive "induction" CD20 B cell depletion consistently modulates pathogenic alloimmunity and attenuates CAV in this translational model, extending our prior findings with calcineurin inhibitors to the context of CD154 blockade.
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Background. Anti-CD154 monotherapy is associated with antidonor allo-antibody (Ab) elaboration, cardiac allograft vasculopathy (CAV), and allograft failure in preclinical primate cell and organ transplant models. In the context of calcineurin inhibitors (CNI), these pathogenic phenomena are delayed by preemptive "induction" B cell depletion. Methods. αCD154 (IDEC-131)-treated cynomolgus monkey heart allograft recipients were given peritransplant rituximab (αCD20) alone or with rabbit antihuman thymocyte globulin. Results. Relative to previously reported reference groups, αCD20 significantly prolonged survival, delayed Ab detection, and attenuated CAV within 3 months in αCD154-treated recipients (αCD154 + αCD20 graft median survival time > 90 days, n = 7, vs 28 days for αCD154 alone (IDEC-131), n = 21; P = 0.05). Addition of rabbit antihuman thymocyte globulin to αCD154 (n = 6) or αCD154 + αCD20 (n = 10) improved graft protection from graft rejection and failure during treatment but was associated with significant morbidity in 8 of 16 recipients (6 infections, 2 drug-related complications). In αCD20-treated animals, detection of antidonor Ab and relatively severe CAV were anticipated by appearance of CD20 + cells (>1% of lymphocytes) in peripheral blood and were associated with low αCD154 trough levels (below 100 μg/mL). Conclusions. These observations support the hypothesis that efficient preemptive "induction" CD20 B cell depletion consistently modulates pathogenic alloimmunity and attenuates CAV in this translational model, extending our prior findings with calcineurin inhibitors to the context of CD154 blockade. A growing body of evidence indicates that B cells provide an important source of donor-specific antigen presentation. Thus, peritransplant depletion of B cells may remove an efficient source of donor antigen-specific costimulation, one potentially pivotal to long-term graft fate. In support of this paradigm, recent reports in cynomolgus monkey models show that preemptive "induction" B cell depletion delayed the onset or attenuated the severity of chronic heart allograft rejection 1 and facilitated prevalent long-term islet allograft survival. 2 These studies and related antecedent work in several other models suggest that B cells play a pivotal and nonredundant role proximal to allo-antibody (Ab) elaboration in the alloimmune response, as in autoimmunity. 3 This evidence has informed 2 prospective randomized clinical trials evaluating B cell depletion with rituximab (Rituxan; Genentech, South San Francisco, CA) for perioperative "induction" in kidney transplant recipients, 4, 5 both showed a trend toward improved outcomes with rituximab. In addition, CD20 depletion has been evaluated at the time that allo-Ab is initially detected in renal allograft recipients (CT0T-2/CCTPT-02: NCT00307125; study enrolment completed).
Here we report that, when combined with selective CD154 inhibition, preemptive "induction" CD20 + B cell depletion attenuates allo-Ab elaboration and inhibits cardiac allograft vasculopathy (CAV) in a preclinical cardiac allograft model. Data are presented in the context of relevant reference groups that have been previously reported. 1, 6 MATERIALS AND METHODS General methods used for this work have previously been described in detail.
1 αCD154 monotherapy, αCD154 + rabbit antihuman thymocyte globulin (rATG), 6 and αCD20 monotherapy 1, 7 groups have previously been reported and are included here for comparison by permission.
Cynomolgus Monkeys
Captive-bred and wild-caught cynomolgus monkeys (Macaca fascicularis) of Chinese and Indonesian origin were used for this study. All procedures were approved by the Institutional Animal Care and Use Committee at the University of Maryland School of Medicine and were conducted in compliance with National Institutes of Health guidelines for the care and use of laboratory animals. Males and females weighing 2.8 to 5.5 kg were selected as organ recipients of ABO blood type-compatible donors of either sex. Stimulation index greater than 3 assured that each donor-recipient pair was major histocompatibility complex class II-mismatched, and pairings were arranged so as to maximize mixed lymphocyte reaction response (median, 18; range, 5.8-73).
Surgical Procedures
Five intended recipients (of 10 in the αCD154 + antithymocyte globulin [ATG] + αCD20 group) underwent endoscopically assisted thymectomy over 2 weeks before transplant. Complete thymectomy was confirmed at subsequent necropsy. As previously reported, 1 some animals treated with αCD154 (5 of 21) or αCD154 + rATG (3 of 6) also receive intrathymic or intravenous (IV) donor bone marrow on the day of transplant.
All recipient animals underwent heterotopic intra-abdominal cardiac transplantation, as described previously. 6, 8 Graft function and core temperature were assessed at least once daily by telemetry (D70-PCTP, Data Sciences International) implanted at the time of transplantation until graft explant. Signs of graft dysfunction (decline in heart rate or developed pressure within the graft of >20% from that recipient's stable postoperative baseline) prompted transabdominal ultrasound and biopsy and/or empiric treatment for presumed rejection. 1 Primary graft survival was defined as time to the first rejection diagnosis and/or treatment. In some animals, suspected or biopsy-confirmed rejection was treated with methylprednisolone (Solu-Medrol; Henry Schein, Melville, NY, Cat. 9086745, 40 mg/kg IV once followed by 20 mg/kg daily for 2 days) and rATG (M51, M327, MB621) or αCD20 (M348). Secondary graft failure was defined by further decline in graft function after previous rejection treatment. Open cardiac biopsies were performed by protocol on postoperative days (PODs) 14 and 28 and monthly thereafter until graft explant whenever clinical condition allowed. Biopsies were occasionally omitted in case of recipient anemia or malaise, which in this series was attributable to a transient parvovirus epidemic, 9 and which had resolved before the current study. Molecular monitoring for cytomegalovirus (CMV) was not performed, and antiviral medications were not used. Surviving grafts were explanted at the protocol-defined study endpoint of 3 months (90-98 days) or at the time of graft failure (M10670, day (d) d112; M9412, d114) after cessation of treatment on d84. Two recipients of grafts implanted before adoption of telemetric monitoring had shrunken, fibrotic grafts removed at exploration on postimplant d230 (M167) and d269 (M1116), respectively.
Experimental Groups and Drug Immunosuppression Dosing
Seventeen cardiac allograft recipients were treated with "high-dose" αCD154 treatment as defined previously 6 (αCD154 [IDEC-131], 30 mg/kg d0, d3, d7, d14; 20 mg/kg d 21, d28, d56, and d84, and chimeric αCD20 Ab (rituximab [Rituxan] , kind gift of Genentech, San Francisco, CA, or purchased commercially; (αCD20); 20 mg/kg IV on the day before transplantation or on the day of surgery, and on PODs 7, 14, and 21. The efficiency of this regimen to deplete peripheral blood and secondary lymphoid tissue B cells in this species has been described previously. 7 Ten recipients were additionally treated with 3 doses of rATG (5-20 mg/kg; Nashville rATG, a kind gift of Tennessee Donor Services; or thymoglobulin, kind gifts from Sangstat and Genzyme). Rabbit antihuman thymocyte globulin was administered every 1 to 3 days within the first week after transplant with antihistamine premedication (diphenhydramine, Benadryl). Previously reported recipients that received no immunosuppression (n = 5) 6, 8 ; αCD20 monotherapy (n = 2) 1 ; IDEC-131 at "high-dose" alone (M51, M147, M62, M350, M643, M327, M10538, M10682, M18, M10670) or with induction ATG (n = 6); or "low-dose" IDEC-131 (n = 11) 6 are included as relevant reference groups.
Trough αCD154 levels were checked retrospectively by enzyme-linked immunosorbent assay, and confirmed that therapeutic target IDEC-131 levels (>100 μg/mL) were achieved within the first months after transplant in most study subjects unless otherwise noted ("Lo" IDEC coverage, Table 1 ). An assay to detect anti-idiotypic Ab against IDEC-131 was not available to us to investigate why some IDEC-131-treated animals exhibited "low" titers during the second month after transplant.
Blood Sampling and Flow Cytometry Staining of Peripheral Lymphocytes
Cell blood counts and B and T lymphocyte subsets were measured by protocol at regular intervals in freshly collected ethylenediaminetetraacetic acid blood using an automated cell counter (Hemavet) and flow cytometry, respectively, as previously described. 1 All antibodies used for flow cytometry (clones SP34, M5E2, and L243) were obtained from BD Pharmingen (San Diego, CA).
Detection of Antidonor Allo-Ab
Allo-antibodies were measured retrospectively by flow cytometry using archived frozen donor splenocytes and recipient sera as described previously. 1, 6, 10 Allo-Ab reactivity was defined as an increase, consistently detected, of more than 10% in the proportion of IgM-positive or IgG-positive donor CD3 + CD20
− T cells relative to donor serum before transplant; levels repeatedly above 20% were interpreted as unequivocal evidence of antidonor allo-Ab elaboration. CAV score: cardiac allograft vasculopathy score. Histologic scores were determined as described in Methods.
e Animals that died with a beating graft before reaching the primary graft survival endpoint or 85 days are censored from the graft survival analysis.
ID, identifier; Bx, graft biopsy; Exp(l), explanted graft; Rx, treatment; AR, acute rejection; BM, bone marrow; IT, intrathymic; d, posttransplant day; ND, nondiagnostic (poor tissue quality); Anes comp Resp Arr, anesthetic complication with respiratory arrest; CR, chronic rejection; Parvo, parvovirus primary infection or reactivation; tech, technical error; fail Rx, failed rejection treatment; SBO, small bowel (obstruction); Elec(tive) Expl, Elective graft explant; Recip thy, recipient thymectomy before transplant; Pulm Infect, pulmonary infection; Funct, functioning graft at explant; Fibr, fibrotic; fix, (graft biopsy tissue) fixation.
Histology and CAV Quantification
Biopsy and explant tissue specimens were fixed with 10% formalin, processed routinely for paraffin embedding, and sections were stained with hematoxylin and eosin. Pericardial granulation tissue was excluded from the rejection and CAV assessments, and biopsies with poor tissue preservation or absence of identifiable myocardial tissue were classified as nondiagnostic (ND). Classification of intramyocardial cellular infiltrates was done according to the 2005 International Society of Heart and Lung Transplantation (ISHLT) revised criteria for cardiac allograft rejection. 11 Cardiac allograft vasculopathy severity was scored in myocardial biopsies and all explanted hearts. All endothelium-lined cardiac vascular structures were scored in each biopsy at multiple levels. In explants a minimum of 20 and up to 50 epicardial arteries and intramyocardial arterioles were evaluated by morphology on hematoxylin-eosin. Three independent evaluators (S.K. or L.B, T.Z., and R.N.P.) were blinded with respect to treatment group. Cardiac allograft vasculopathy was graded and adjudicated as previously described. 1 Immunochemistry staining for B cells was performed on formalin-fixed paraffin-embedded tissue sections using an automated method and B cell staining was scored by 2 blinded investigators (A.M.A., A.H.) on a scale of 0 to 4 as previously described.
B Cell-Activating Factor Levels
Serum levels of B cell-activating factor (BAFF) were measured on archived samples using human BAFF/BLyS/TNFSF13B Quantikine ELISA Kit (R&D System, Minneapolis, MN).
Statistical Analysis
Nominal variables (incidence of early rejection) were compared using a contingency table and the Fisher exact test. Continuous variables (CAV score) were expressed as the mean plus standard deviation unless otherwise indicated and were compared using the 2-tailed unpaired t test. P values less than 0.05 were considered statistically significant. All statistical analyses were performed on a personal computer with GraphPad InStat (version 3.01; GraphPad Software, San Diego, CA).
RESULTS
Administration of 4 weekly doses of rituximab efficiently depleted B cells in peripheral blood in all treated animals (Fig. S1 , SDC, http://links.lww.com/TP/B279), as in our previous reports.
1,7 B cells typically comprised less than 1% of peripheral blood lymphocytes for at least 30 days after cessation of treatment, and absolute B cell numbers typically remained less than 50 per μL. T cell numbers in peripheral blood were not decreased by αCD20 treatment as expected based on our previous experience. 1 In contrast, T cell numbers were dramatically decreased by additional rATG therapy and remained low for about 2 months thereafter they slowly recovered (Fig. S1 , SDC, http://links.lww.com/TP/B279). Table 1 ). In contrast, 3 of 20 evaluable αCD154-treated recipients (MST 28 days, range 6-> 90; P = 0.05 vs CD154 + αCD20) (1 censored for anemia on d21) and 1 of 3 evaluable αCD154 + ATG-treated animals (MST 74 days, range >25-> 90; P = 1.0 vs αCD154 + αCD20; P = 0.45 vs αCD154) (3 censored for infectious death) exhibited graft survival to day 90. Addition of rATG to αCD154 + αCD20 was associated with survival to elective explant around 90 days in 3 of the 4 evaluable grafts in this group (P = 0.35 vs αCD154; P = 0.49 vs αCD154 + rATG; 6 other animals treated with this regimen died with histologically normal grafts due to rATG reaction (2); surgical complications (1); or infection (3) (detailed above). Considered in aggregate, treatment with αCD20 was associated with significantly higher incidence of survival to day 90 (7/10) relative to αCD154 ± rATG without αCD20 (4/23) (P = 0.006).
Effect of aCD20 on ISHLT Cellular Rejection Score
As previously reported, without immunosuppression or with αCD154 or αCD20 monotherapy, failed grafts revealed severe acute rejection, with hemorrhagic necrosis and variable degrees of cellular infiltration at explant (Table 1 , ISHLT columns). 1, 6 With CD154 monotherapy, all early explants (11 of 11 removed within 30 days) displayed acute rejection (2 mild, 9 severe), and 9 of 10 grafts that survived beyond 1 month displayed mild (1), moderate (1), or severe (7) acute rejection on biopsy or at explant. With αCD154 + rATG treatment, severe rejection was present at explant in 2 of 3 functioning grafts removed by POD 41, and mild (1R) or moderate (2R) rejection was observed in 2 of 3 electively explanted grafts from this group.
In contrast, αCD20 + αCD154 was associated with a significantly reduced incidence of severe acute rejection (>1R) within 30 (0% vs 52% with αCD154 alone; n = 7 and 21 respectively; P = 0.023) and 60 days (17% vs 75% with αCD154 alone; n = 6 and 20, respectively; P = 0.018) [1 graft in each group was censored between 30 and 60 days due to recipient death with a beating graft]. Only 1 αCD154 + αCD20 FIGURE 1. Primary graft survival by treatment regimen. Cynomolgus monkey recipients of major histocompatibility complexmismatched heterotopic cardiac allografts were treated with αCD154 alone (blue line) or with additional rATG (green line), or αCD20 (red line), or both antibody preparations (black line). Graft function was monitored by telemetric ECG and pressure waveforms. Historical controls that were either untreated or given αCD20 alone are not shown (see Table 1 6,12 ). Clinical rejection was treated in some animals as indicated in Table 1 . Addition of αCD20 to αCD154 prolonged rejection-free primary graft survival (P < 0.05 vs αCD154 alone). Numbers in parentheses indicate grafts without clinical rejection by 90 days/uncensored grafts at risk.
graft was lost to acute rejection (MB621, ATG-resistant), and rejection was absent (4) or mild (1) within the first 2 months in theother5recipientsinthisgroup.WithαCD154+αCD20+rATG, only 1 animal of 10 (MA021) exhibited graft loss due to acute rejection within 2 months. With αCD154 + αCD20, with or without rATG, ISHLT rejection scores at functioning graft explant or recipient demise revealed absent or mild graft rejection (ISHLT score, 0-1R) in 6 of 10 animals with recipient and graft survival longer than 1 month, and in 12 of 14 protocol biopsies.
Effect of aCD20 on Antidonor Allo-Ab Elaboration
As previously reported, αCD154 monotherapy is associated with prevalent elaboration of antidonor Ab. 6 Allo-Ab was detected in all αCD154 monotherapy animals with graft failure by 21 days (not illustrated here for clarity; see Azimzadeh et al 6 ). Among the subset of recipients in this group with grafts surviving longer than 21 days, 11 of 12 treated with αCD154 exhibited antidonor Ab, with most (10 of 12) mounting unequivocally elevated titers within the first months after transplant (Figure 2, top row) .
In 3 of the 7 αCD154 + αCD20-treated recipients, antidonor IgM and IgG allo-Ab were consistently detected beginning between 35 and 80 days after transplant; 3 of the remaining 4 animals exhibited no detectable antidonor Ab by elective sacrifice at 90 days, with transient low levels (~10%) of antidonor IgG (only) detected in MB301 shortly before elective graft explant. (Figure 2 , second row) In FIGURE 2. Allo-antibody production in various treatment groups. IgM (left) and IgG (right) antidonor antibodies were measured by flow cytometry in serum collected serially (weekly for a month, biweekly thereafter) after cardiac allotransplantation as described in Methods. With addition of αCD20, allo-antibody was detected (levels repeatedly above 20%) only when αCD154 antibody levels were low and/or B cell depletion less durable.
contrast, 4 of 5 αCD154 + rATG-treated recipients that were evaluable (M19 did not have viable donor lymphocytes for study) elaborated antidonor Ab before day 56 (Figure 2 , third row), with 3 of 5 mounting unequivocally elevated titers within the first month. Six of 10 recipients treated with αCD154 + αCD20 + rATG exhibited an unexplained, transient early peak in IgM and IgG, not seen with rATG or αCD20, or in our prior report with cyclosporine A + αCD20 (Figure 2, fourth row) . Addition of rATG to αCD154 + αCD20 1 was associated with antidonor allo-Ab detection in only 1 (MA021) of 4 animals available for assessment beyond the first month.
Association Between Trough aCD154 Levels, Allo-Ab Elaboration, and Graft Outcomes Low IDEC-131 trough levels between 21 and 60 days correlated closely with the appearance of antidonor Ab with αCD154 + αCD20 treatment (MB621, DJ2F1, DL1K2) and with additional rATG (MA021). All 3 (of 7) αCD154 + αCD20-treated recipients with a trough IDEC-131 level less than 100 μg/mL elaborated antidonor IgM and IgG greater than 20% before day 90; 2 of these grafts failed in association with acute rejection and CAV before 90 days (MB621, DJ2F1), and the third (DL1K2) exhibited mild acute rejection (1R) and moderately severe CAV (1.8) at graft explant (Table 1) . In contrast, none of the animals in this group with trough levels consistently greater than 100 μg/mL had detectable antidonor Ab, and all their grafts survived longer than 90 days. In MB301, with trough IDEC-131 levels consistently greater than 100 μg/mL, low levels of antidonor IgG (only) appeared transiently during the second month and were detected again (<20%) at elective sacrifice on d93.
Uniquely in the αCD154 + αCD20 + rATG group, MA021 developed rapidly rising antidonor Ab titers on d46 in the setting of low IDEC-131 levels (<10 μg/mL) and graft dysfunction, with severe acute rejection (3R) and moderate CAV (1.8) on histology. Antidonor Ab was not detected in other αCD154 + αCD20 + rATG-treated animals with trough IDEC-131 levels above (M9412) or intermittently below (M9387, 30-68; MB030, 57-68) our target trough of 100 μg/mL.
Effect of aCD20 on Graft CAV
With αCD154 monotherapy, 18 of 21 evaluable heart allografts exhibited acute (8) or acute and chronic rejection (10) before d90, with severe CAV (>2.0) or graft fibrosis at explant in 2 of the remaining 3 grafts in this group. (Figure 3 , Table 1 , CAV columns) αCD154 + rATG treatment was associated with moderate (1.3, M19) to severe (2.1-2.7) CAV in every graft surviving beyond 1 month (3 animals were euthanized for parvovirus-associated anemia by POD 41).
Cardiac allograft vasculopathy lesions were less severe within 3 months after transplantation in association with addition of CD20 depletion to αCD154 (mean CAV score, 1.2 ± 0.9 in 6 grafts surviving at least 1 month; median, 1.55; range, 0-2.2), significantly lower than that was seen among 11 grafts surviving at least 1 month with αCD154 alone (2.2 ± 0.7; median, 2.3; range, 0.1-2.8; P = 0.03 vs αCD154 + αCD20) or in 5 recipients treated with αCD154 + rATG (2.3 ± 0.6; median, 2.6; range, 1.3-2.7; P = 0.05 vs αCD154 + αCD20) ( Table 1) .
When "therapeutic" trough CD154 levels were achieved and antidonor Ab was not detected, αCD154 + αCD20 was associated with minimal CAV at graft explant (0-0.2 in MA985, MA008, MA053). In MB301 mild-moderate CAV (1.3) at elective graft explant on d93 was associated with moderate acute cellular rejection, trough IDEC-131 greater than 100, and low but increasing titers of antidonor IgG. With αCD154 + αCD20 + rATG, moderate CAV (1.8) was present in MA021's graft that was acutely rejected in the context of high and rising antidonor Ab levels. Mildmoderate CAV (1.2) was present in M9412, explanted in the context of deteriorating graft function and mild acute cellular rejection on d114, 30 days after the last dose of IDEC-131. Cardiac allograft vasculopathy was minimal in the other grafts in this group, including 2 long-term surviving grafts that were electively explanted at 3 months (MB9387, 0.5; MB030, 0). 3 . B cell depletion inhibits CAV. A, Representative pictures from cardiac allografts explanted at graft failure (M350; M643; αCD154 therapy; original magnification, Â100) or at approximately day 90 (MA008; MB301; αCD154 + αCD20 therapy; original magnification, Â200) and stained with H&E. Vascular intimal proliferative lesions are prominent with αCD154 monotherapy, but not with additional αCD20. Perivascular cellular infiltration and some degree of hemorrhage and endothelial activation were detected in rejected allografts, consistent with cellular and humoral immune injury. B, Median quantitative severity scores are shown for explanted grafts surviving for >21 days that were treated with αCD154 (n = 11) and rATG (n = 5), αCD20 (n = 6), or αCD20 + rATG. *P < 0.05 vs αCD154 alone. H&E, hematoxylin-eosin.
Detection of Circulating B Cells Anticipates Detection of Allo-Ab
Initial B cell depletion was efficient (>95%) in all recipients treated with αCD20 (Fig. S1 , SDC, http://links.lww.com/TP/ B279). In some recipients treated with αCD154 + αCD20, peripheral blood B cell counts, as a percent of circulating lymphocytes, recovered to greater than 5% of peripheral blood lymphocytes between d40 (MB621, 5-9%) and d84 (DL1K2, 7%; DJ2F1, 30%) by the time allo-Ab was detected on d42, d56, and d90, respectively. In each instance (MB621, DL1K2, DJ2F1) intragraft B cells were also detected (Figure 4) . B cell counts greater than 2% anticipated allo-Ab detection by 2 to 4 weeks in both animals where an informative flow cytometric analysis was available (MB621, d27; DL1K2, d48). Similarly, B cell recovery to 2.5% (d27) and 14% (d46) was detected in MA021 (αCD154 + αCD20 + rATG), and anticipated first detection of allo-Ab on d42. In contrast, peripheral B cell counts remained consistently less than 2% until d90 in all αCD154 + αCD20 and αCD154 + αCD20 + rATGtreated animals in that antidonor Ab was not detected, including MB301 (0.6% at d93), and intragraft B cell infiltration was absent or rare in all other graft explants evaluated (Figure 4) .
Effect of aCD20 on BAFF Levels
Serum BAFF levels consistently increased within 2 weeks after B depletion, whether αCD20 was given alone, or combined with αCD154 or αCD154 + rATG ( Figure 5 , right panels), whereas BAFF levels rose only modestly and inconsistently in the context of control regimens lacking αCD20 ( Figure 5 , left panels). The profile of BAFF levels in B cell-depleted animals was very heterogeneous, and no obvious correlation was found between levels or kinetics of BAFF and allo-Ab or CAV.
Treatment-Associated Morbidity
B cell depletion combined with αCD154 was generally well tolerated, without clinical evidence of unusual susceptibility to infection despite omission of antiviral prophylaxis. treated with this regimen: acute pulmonary edema was temporally associated with rATG infusion in 2 recipients [M9389, M9399]; 2 lung infections were identified at necropsy, 1 ascribed to CMV [MA094] , and the other with no identified organism [M9397]; severe anemia associated with epidemic simian parvovirus infection 9 triggered euthanasia by protocol in 1 recipient [MA036] ( Table 1 , clinical notes). The incidence of symptomatic viral infection αCD154 + αCD20 + rATG (3 of 7 at risk) was similar to that observed with αCD154 + ATG (3 acute primary parvovirus infections that were associated with severe anemia, of 6 at risk). In 1 αCD154 + αCD20 animal (MA985) of 7 in this group, CMV was diagnosed incidentally on lung histology after euthanasia for isolated severe anemia due to documented acute parvovirus infection. Epidemic parvovirus acute infection with severe anemia required sacrifice in 1 animal (M62) with a functioning graft treated with αCD154 alone, as previously reported. 9 Two experiments were terminated due to surgical complications: 1 animal (MA015) was euthanized due to small bowel obstruction associated with a retained surgical gauze on POD 12; another was sacrificed after incurring a small bowel injury at exploration for planned biopsy (MA008). One animal (M922) with a histologically normal functioning graft died on POD 85 after anesthesia with no pathology identified at necropsy.
DISCUSSION
Impressive improvements in the efficacy of organ transplantation over the past 60 years are attributable in large measure to availability of an expanding array of immunosuppressive agents, combined with the use of lymphocyte infiltration in graft biopsies as the principal barometer of pathogenic alloimmunity, one that guides adjustment of immunosuppression intensity. However, during the last 2 decades, serologic, FIGURE 5. B cell depletion increased serum BAFF levels. Serum BAFF levels were measured at d0, 7, 14, 21, 28, 35,~50, 64, 84 , and 90 in recipients of a cardiac transplantation. BAFF levels increased after transplantation in all groups, but the increase was more modest in untreated controls (3.8 ± 1.8 fold on d7 vs baseline, n = 5) compared with αCD20 monotherapy (11.3 ± 4.5, n = 2, P = 0.95). BAFF increased to similar levels as untreated controls in graft recipients treated with αCD154 with or without ATG (3.4 ± 0.8 fold on d28 vs baseline, n = 5), whereas levels were dramatically increased with αCD20-based regimens (12.8 ± 7.7, n = 7, P = 0.03). The longitudinal profile of BAFF levels in B cell-depleted animals was very heterogeneous, and no obvious correlation was found between levels or kinetics of BAFF and allo-antibody or CAV. Therefore, B cell depletion was associated with an increase in BAFF levels compared with reference groups.
immunohistologic, and molecular tools with improved sensitivity and specificity have strongly implicated antidonor allo-Ab in the pathogenesis of both acute and chronic clinical allograft rejection. 14, 15 Detection of allo-Ab in association with graft pathology implicates donor antigen-specific B cells as an important contributor to graft injury and identifies them as a potential therapeutic target. B cell depletion has been used safely for other indications in oncology, 16 autoimmunity, 17 and in presensitized transplant patients. 18, 19 Here, we extend our cardinal observation in a preclinical solid organ allograft model, 1 confirming for the context of CD154 blockade that B cells exert a pivotal influence during the initiation of alloimmunity by showing that their efficient depletion around the time of transplant is associated with significant protection from acute and chronic rejection. This observation confirms and extends similar findings in rodent heart transplant recipients 20, 21 and in a monkey islet allograft model. 2 Intensity of CD154 treatment (IDEC-131 trough level, and by inference CD40/154 signaling blockade) influenced efficacy, because only those animals with "low" trough IDEC-131 levels (<100 μg/mL) elaborated detectable allo-Ab and manifested relatively accelerated CAV while being treated with αCD154 Ab. Variability in outcomes within the αCD154 + αCD20 (+/−rATG) groups also appeared to be associated with early reappearance of circulating B cells in peripheral blood, which in turn anticipated elaboration of antidonor allo-Ab and CAV. These associations-similar to those we previously described for cyclosporine A + αCD20-add further support to the mechanistically plausible hypothesis that humoral alloimmunity is pathogenic and causally related to clinical chronic rejection. Further, they implicate both B cell-driven antigen-presenting cells function and incomplete CD154 costimulation pathway inhibition in CAV's pathogenesis. Finally, we hypothesize that B cell monitoring may reliably identify an immunologic "window of opportunity" for intervening in the immune response to alloantigens after B celldepleting "induction" treatment. Serum BAFF levels were consistently increased at higher levels in αCD20 depleted groups compared with control regimens, suggesting BAFF as a marker for B cell depletion as reported in autoimmune diseases. [22] [23] [24] Strategies that do prevent subsequent elaboration of allo-Ab should be evident within a few months after B cell recovery and would be expected to delay or even prevent subsequent CAV in our model. If confirmed in humans, detection of B cells could be used to efficiently evaluate candidate strategies designed to redirect the emerging immune response to prevent elaboration of pathogenic allo-Ab, and eventually toward induction of durable tolerance. Each of these conclusions has important implications as the basis for logical, testable strategies to inhibit allo-Ab elaboration and perhaps improve outcomes in clinical heart transplantation, and perhaps other organ and cell transplants.
Side effects and toxicities associated calcineurin inhibitor (CNI) therapy motivate efforts to develop CNI-free alternative regimens, including costimulation pathway blocking agents. Our current observations predict that combining B cell depletion with costimulation pathway blockadewith either belatacept, 25, 26 one of the emerging αCD40/CD154 reagents, 12 or selective, nonactivating CD28 blockade 27, 28 will prove safe and efficacious in reducing the risk of early acute rejection in humans. On the other hand, our data raise concerns that viral infections are likely to be problematic if additional anti-T cell (ATG) or more broadly depleting agents (eg, alemtuzumab) were added to one of these regimens. Meanwhile, the safety profile of an αCD154 peggylated Fab to treat autoimmune disease is being evaluated in a phase 1 clinical trial (NCT01764594), underscoring the potential clinical relevance of our ongoing work on this pathway. 29 Detection of evanescent antidonor IgM and IgG in the majority of recipients treated with αCD154 + αCD20 + rATG was unexpected. Absence on the day of transplant, rapid disappearance after 14 days, and sustained "negative" results in 3 of 4 animals with long-term follow-up suggest that the "positive" signal does not reflect transient elaboration of antidonor Ab. False-positive crossmatch results in humans treated with αCD20 have been ascribed to Fcγ-receptor binding by αCD20, particularly in the setting of autoimmunity. 30 We speculate that high recipient serum levels of rATG and αCD20, residual in the context of the associated profound recipient lymphopenia, may mimic autoimmunity (type III systemic immune complexes) when recipient serum is then exposed to donor leukocytes. Presence of preformed macaque antirabbit Ab (which would bind to rATG bound to donor lymphocytes) only in these particular recipients is possible, but seems unlikely.
We have previously reviewed the role of B cells in the onset and progression of CAV lesions in various other transplant models.
1 B cell depletion may operate primarily by altering the anatomy of primate secondary lymphoid organs, 7 by "incidentally" depleting high-affinity donor-reactive B cells, or by a combination of both mechanisms: our current observations remain compatible with either model. In addition, it may regulate nonredundant antigen-presenting functions previously ascribed mainly to other "professional" antigenpresenting cells, either directly, or through the production of allo-Ab acting as opsonins. The panoply of informative tools available to apply in much larger numbers of experimental subjects continues to recommend rodent models and human clinical trials for determining their relative importance.
In summary, preemptive B cell depletion combined with CD154 blockade attenuates both T and B cell-mediated pathogenic immunity, and delays or prevents chronic rejection in those experimental subjects who exhibit efficient, sustained B cell clearance. Our current observation confirms that the immune response to an allograft is particularly susceptible to B cell depletion, and that B cells play a pivotal role at a proximal point in the evolution of the pathogenic immune response to an allograft. Extending our prior findings with αCD20 treatment in the context of CNI-based immunosuppression, the current data underscore the potential value of preemptive B cell depletion as a novel adjunct to delay or prevent chronic rejection after transplantation of the heart, which prove salient to other solid organ and cellular allografts. Until a clinically feasible approach to specifically target donor-reactive B cells can be devised, 31 preemptive "induction" CD20 + B cell depletion represents a clinically applicable strategy to delay or potentially prevent antidonor allo-Ab elaboration and CAV.
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